The TIAA CREF Investment Management LLC Has $6.21 Million Stake in Prothena Corporation PLC (NASDAQ:PRTA)

The TIAA CREF Investment Management LLC Has $6.21 Million Stake in Prothena Corporation PLC (NASDAQ:PRTA)

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of Prothena Corporation PLC during the fourth quarter valued at $528,000. State Street Corp increased its position in shares of Prothena Corporation PLC by 1.3% in the fourth quarter. State Street Corp now owns 1,085,411 shares of the biotechnology company’s stock valued at $53,392,000 after buying an additional 13,694 shares during the period. Norges Bank acquired a new position in shares of Prothena Corporation PLC during the fourth quarter valued at $18,277,000. Teachers Advisors LLC increased its position in shares of Prothena Corporation PLC by 5.6% in the fourth quarter. Teachers Advisors LLC now owns 72,604 shares of the biotechnology company’s stock valued at $3,571,000 after buying an additional 3,849 shares during the period. Finally, Fisher Asset Management LLC increased its position in shares of Prothena Corporation PLC by 26.0% in the first quarter. Fisher Asset Management LLC now owns 13,503 shares of the biotechnology company’s stock valued at $753,000 after buying an additional 2,785 shares during the period.

TIAA CREF Investment Management LLC decreased its stake in Prothena Corporation PLC (NASDAQ:PRTA) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,386 shares of the biotechnology company’s stock after selling 5,992 shares during the period. TIAA CREF Investment Management LLC owned about 0.32% of Prothena Corporation PLC worth $6,214,000 as of its most recent filing with the SEC.

Shares of Prothena Corporation PLC (PRTA) traded down 0.56% during midday trading on Wednesday, hitting $60.11. 225,079 shares of the stock were exchanged. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The firm’s market cap is $2.29 billion. The stock’s 50 day moving average is $59.43 and its 200 day moving average is $54.43.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.33. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million. During the same period in the prior year, the firm posted ($0.81) earnings per share. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, equities research analysts forecast that Prothena Corporation PLC will post ($4.76) earnings per share for the current fiscal year.

Several brokerages have weighed in on PRTA. BidaskClub upgraded Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 19th. Jefferies Group LLC started coverage on shares of Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 price objective for the company. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $70.00 price objective on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Piper Jaffray Companies reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Tuesday, May 16th. Finally, BTIG Research began coverage on shares of Prothena Corporation PLC in a research note on Friday, May 19th. They set a “buy” rating and a $80.00 price objective for the company. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $75.69.

In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $58.11, for a total value of $203,385.00. Following the transaction, the director now directly owns 6,345 shares in the company, valued at $368,707.95. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $64.89, for a total transaction of $324,450.00. Following the completion of the transaction, the insider now owns 5,000 shares in the company, valued at $324,450. The disclosure for this sale can be found here. 3.10% of the stock is owned by insiders.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Related posts

Leave a Comment